Retatrutide and Dysesthesia: The Skin-Sensitivity Side Effect Explained

Written by Olha Orlyk. Updated October 30, 2026.

Dysesthesia is an unusual, often unpleasant skin sensation, such as burning, tingling, prickling or skin that hurts to touch, and it has become the side effect most closely associated with retatrutide. In every phase 3 trial reported so far, people on retatrutide reported it more often than people on placebo, and more often at higher doses: from 2% to 5% at the lowest doses up to 12.5% at the highest dose in TRIUMPH-1 and 20.9% in the knee-arthritis trial TRIUMPH-4, against 0% to 1.3% on placebo. Lilly describes the cases as generally mild to moderate, says most resolved while people stayed on treatment, and says they rarely led anyone to stop. Why it happens is not known. It is not unique to retatrutide: the Wegovy label now lists it, at 22% with the new 7.2 mg dose. This guide sets out the numbers trial by trial, what is and is not known about how long it lasts and why it occurs, and when skin symptoms need a doctor.

Dysesthesia is a medical term for a set of abnormal touch-related sensations. People describe burning, tingling, prickling, crawling or electric feelings, or skin that is unusually sensitive to clothing, sheets or a light touch. Paresthesia, the 'pins and needles' feeling, is one type. Allodynia is a related term for pain caused by touch that should not hurt. Dysesthesia can occur with many conditions, from diabetes and vitamin deficiencies to shingles, and in many cases no single cause is found. In the retatrutide trials, Lilly grouped these sensations together, defining dysesthesia as a skin burning sensation and related adverse events.

Lilly has reported dysesthesia rates for five phase 3 trials in press releases between December 2025 and July 2026. The pattern is consistent: rare on placebo, more common on retatrutide, and generally more common at the higher doses. Retatrutide was studied at weekly doses of 4 mg, 9 mg and 12 mg; how the trials escalated doses is explained in retatrutide dosage in clinical trials.

The highest rate, 20.9% at 12 mg in TRIUMPH-4, has not been explained. That trial enrolled people with knee osteoarthritis, but no published analysis links the higher rate to the joint condition, the trial length or the population, so any explanation would be speculation. The rates in people with type 2 diabetes were lower than in people without it. Full results of the obesity and diabetes trials are summarised in TRIUMPH-2 and TRIUMPH-3 results.

The 2023 phase 2 obesity trial, published in the New England Journal of Medicine, did not use 'dysesthesia' as a combined term, which is why some reports said it was not seen in phase 2. Its supplementary tables do list related sensations recorded individually: hyperesthesia (increased skin sensitivity) in up to 6.1% of one retatrutide group against 1.4% on placebo, 'sensitive skin' in up to 5.7% against none on placebo, and allodynia in 6.5% of the 12 mg group against none on placebo. The signal was therefore present from the start, under different names.

Lilly's descriptions are consistent across trials. In TRIUMPH-4 it said the events were generally mild and rarely led to stopping treatment. In TRANSCEND-T2D-1 it said they were generally mild, with a majority resolving during treatment. In TRIUMPH-1, TRIUMPH-2 and TRIUMPH-3 it described them as generally mild to moderate, with most resolving and most participants continuing treatment. What Lilly has not published is a dysesthesia-specific discontinuation rate, a breakdown by severity, or the typical time to onset and resolution. Overall discontinuation for any adverse event in TRIUMPH-1 was 4.1%, 6.9% and 11.3% on the three doses against 4.9% on placebo, but those figures include all side effects, mostly gastrointestinal.

This is the main gap in the data. Lilly says most cases resolved while people continued treatment, which suggests that for many people the sensations are temporary, but it has not published how long they lasted. The best comparison comes from the Wegovy label for the 7.2 mg dose, where the effect is better documented: among people who reported dysesthesia, 2% stopped permanently, 8% paused treatment, 23% had their dose reduced, and 18% had not reported recovery by the end of the trial. Of those whose dose was increased again, 45% had the symptoms return. Whether retatrutide behaves the same way is not yet known; the full journal papers for TRIUMPH-1 and TRIUMPH-2, published in September 2026, may hold more detail.

No one knows, and the explanations below are hypotheses rather than established facts. Retatrutide activates three hormone receptors, GLP-1, GIP and glucagon, as explained in what is GLP-3 RT. One idea is that receptors for these hormones on sensory nerves are involved. A second is that rapid weight loss and lower food intake temporarily shift levels of B vitamins or electrolytes that nerves depend on. Neither has been tested in the retatrutide trials. One useful clue: semaglutide, which acts only on the GLP-1 receptor, also causes dysesthesia in a dose-dependent way, so the glucagon component cannot be the whole explanation, although it could add to the rate.

The Wegovy label states that the incidence of dysesthesia increased with increasing dose and blood levels of the drug, the same pattern seen with retatrutide. In April 2026 UK product information for Rybelsus and Ozempic was updated to list dysaesthesia, and New Zealand's medicines regulator has advised clinicians to consider GLP-1 drugs as a possible cause of altered skin sensations. Tirzepatide's rate is much lower. How retatrutide compares with tirzepatide more broadly is covered in retatrutide vs tirzepatide.

There is no evidence that retatrutide dysesthesia reflects permanent nerve damage; most cases resolved during treatment. But burning or tingling skin has many causes, some of which need treatment, so new or persistent symptoms deserve assessment rather than an assumption that the drug is responsible.

Retatrutide is not approved anywhere; Lilly plans to file with the FDA in the first quarter of 2027, as tracked in when will retatrutide be approved. The FDA says retatrutide cannot be used in compounding under federal law, has not been found safe and effective for any condition, and has warned sellers of products falsely labeled 'for research purposes'. Public Citizen reported 14 hospitalizations linked to such products in June 2026, and Lilly sued six sellers in August 2026. Side-effect rates from Lilly's trials do not apply to products of unknown content and dose. The only legitimate way to receive retatrutide today is in a clinical trial, as explained in how to get retatrutide.

Dysesthesia, a burning, tingling or sensitive-skin sensation, is a real and dose-related side effect of retatrutide, reported in 2% to 21% of people across trials against about 1% on placebo. Lilly describes it as mostly mild to moderate and usually resolving without stopping treatment, but how long it lasts and why it happens have not been published. Semaglutide shows the same signal at its highest dose, so it may be a class effect of very potent incretin drugs. Anyone with new, spreading or persistent skin symptoms should see a doctor. The latest trial and regulatory updates are collected in retatrutide news, and the drug's other effects in retatrutide benefits.

Retatrutide is an investigational drug and is not approved for any use. This article summarizes published trial reports for general information and is not medical advice.